-
Coreline Soft expands global lung AI footprint with French project, Boehringer Ingelheim Taiwan partnership
28 May 2025 08:28 GMT
… a strong entry barrier for competitors and ensures long-term … AVIEW Lung Texture software to Boehringer Ingelheim Taiwan.
Boehringer Ingelheim plans to deploy the … tracking of treatment response.
“Boehringer Ingelheim’s decision to directly purchase …
-
Non-Cystic Fibrosis Bronchiectasis Market Research 2025-2035, Competitive Analysis Of Astrazeneca, Sanofi, Insmed, Boehringer Ingelheim, Zambon, Chiesi, Haisco, Regeneron
23 May 2025 10:16 GMT
… AstraZeneca, GlaxoSmithKline (GSK), Novartis, Boehringer Ingelheim, Pfizer, Vertex Pharmaceuticals, Genentech ( … Competitive Landscape AstraZeneca Sanofi Insmed Boehringer Ingelheim Zambon Chiesi Pharmaceuticals Haisco …
4.2.3 Top Competitors
4.2.4 Target …
-
Interview: Markus Schümmelfeder, CIO, Boehringer Ingelheim
16 Apr 2025 14:37 GMT
… ways to help biopharmaceutical giant Boehringer Ingelheim exploit digital and data. He … we were slower than our competitors in executing clinical trials. We … the business community”
Markus Schümmelfeder, Boehringer Ingelheim
Another key area of research …
-
Weight Loss Drugs Market Global Research 2025-2035 Featuring Eli Lilly, Pfizer, F. Hoffmann-La Roche, GSK, Sun Pharma, Amgen, Rhythm Pharma, Currax, Boehringer Ingelheim, Vivus, Gelesis, Novo Nordisk - ResearchAndMarkets.com
08 Apr 2025 15:02 GMT
… Pharmaceuticals, Currax Holdings USA LLC, Boehringer Ingelheim, Vivus Inc., Gelesis, and Novo … Pharmaceuticals
Currax Holdings USA LLC
Boehringer Ingelheim
Vivus Inc.
Gelesis
Key Topics … ;Offering
11.2.3 Key Competitors
11.2.4 Target Customers …
-
Equine Healthcare Market Generated Opportunities, Future Scope by 2031 | Affymetrix Inc., Boehringer Ingelheim
14 Jan 2025 05:50 GMT
… offers a comprehensive analysis of competitors and Market share information, helping … in This Report:
• Affymetrix Inc.
• Boehringer Ingelheim
• Merck
• Bayer Health Care and … interviews with industry stakeholders and competitors, as well as validation …
-
Animal Health Business Research Report 2024-2030 Featuring Major Players - Bayer, Boehringer Ingelheim, Ceva Sante Animale, Elanco, Heska, Merck, Nutreco, Vetiquinol, Virbac, And Zoetis
09 Jan 2025 09:45 GMT
… Market such as Bayer AG, Boehringer Ingelheim GmbH, Ceva Sante Animale, Elanco … Animal Health - Global Key Competitors Percentage Market Share in 2024 … market report include: Bayer AG Boehringer Ingelheim GmbH Ceva Sante Animale Elanco …
-
C3-Binding Polypeptide by Boehringer Ingelheim International for Unspecified Ophthalmological Disorders: Likelihood of Approval
06 Jan 2025 02:39 GMT
… by targeting complement C3.
Boehringer Ingelheim International overview
Boehringer Ingelheim International (Boehringer), a subsidiary … future-proof advantage over your competitors.
Be better informed
GlobalData, the …
-
Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight
11 Jul 2025 00:14 GMT
… .
Emerging Therapies
9.1.
Key Competitors
9.2.
ECT204: Eureka Therapeutics … key NSCLC companies, including AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson …
-
Boehringer Ingelheim offers Humira biosimilar at 92% discount
19 Jul 2024 18:57 GMT
… 11 competitors have come to market with copycat drugs. Boehringer Ingelheim joined the … Amjevita and Hulio.
However, Boehringer Ingelheim had an underwhelming rollout with … the Humira biosimilar market.
Boehringer Ingelheim’s value and access senior …
-
Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight
08 Jul 2025 22:30 GMT
…
Marketed Drugs
10.1
Key Competitors
10.2
ZIIHERA (zanidatamab): Zymeworks …
Emerging Drugs
11.1
Key Competitors
11.2
CA-170: Aurigene … key NSCLC companies, including AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson …
About
© 1995-2025